Nyxoah S.A. (NASDAQ:NYXH) Sees Large Growth in Short Interest

Nyxoah S.A. (NASDAQ:NYXH) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 100,200 shares, a growth of 27.2% from the February 13th total of 78,800 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average daily volume of 43,000 shares, the days-to-cover ratio is currently 2.3 days.

Institutional Investors Weigh In On Nyxoah

A number of institutional investors have recently bought and sold shares of NYXH. Kovack Advisors Inc. acquired a new stake in shares of Nyxoah during the 3rd quarter valued at about $96,000. LPL Financial LLC acquired a new stake in shares of Nyxoah during the 4th quarter valued at about $102,000. Walleye Capital LLC lifted its holdings in shares of Nyxoah by 23.9% during the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock valued at $119,000 after buying an additional 2,862 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Nyxoah during the 4th quarter valued at about $135,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Nyxoah by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after buying an additional 2,774 shares during the last quarter.

Nyxoah Stock Down 1.0 %

NASDAQ NYXH traded down $0.10 during trading on Monday, reaching $10.41. 161,515 shares of the company’s stock were exchanged, compared to its average volume of 44,968. Nyxoah has a fifty-two week low of $6.76 and a fifty-two week high of $20.00. The firm has a market capitalization of $354.56 million, a PE ratio of -5.57 and a beta of 1.42. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. The company’s fifty day simple moving average is $10.29 and its 200-day simple moving average is $9.19.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $2.02 million. Sell-side analysts predict that Nyxoah will post -1.91 EPS for the current year.

Wall Street Analysts Forecast Growth

NYXH has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their price target on Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Nyxoah in a research report on Friday, December 13th.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.